Ultragenyx Pharmaceutical Cash Flow Statement
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ultragenyx Pharmaceutical free cash flow
In fiscal 2025, Ultragenyx Pharmaceutical generated -$466.0 million of operating cash flow and spent $6.0 million on capital expenditures. That left free cash flow of -$472.0 million, a free-cash-flow margin of -70.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Ultragenyx Pharmaceutical cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -575.00M | -569.00M | -607.00M | -707.42M | -454.02M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 35.00M | 36.00M | 26.00M | 18.22M | 13.24M | 12.26M | 8.54M | 19.54M | 5.83M | 3.42M |
| Stock-Based Compensation | 153.00M | 158.00M | 135.00M | 130.37M | 104.98M | 85.73M | 82.00M | 80.11M | 68.01M | 48.31M |
| Change in Working Capital | -37.00M | -45.00M | -14.68M | -17.97M | -38.06M | 11.24M | -32.77M | -23.78M | 643.00K | -4.64M |
| Operating Cash Flow | -466.00M | -414.00M | -475.00M | -380.46M | -338.69M | -132.22M | -345.38M | -290.57M | -253.84M | -160.97M |
| Capital Expenditures | -6.00M | -7.00M | -44.00M | -116.12M | -73.09M | -43.91M | -24.83M | -4.08M | -2.79M | -10.19M |
| Investing Cash Flow | 236.00M | -18.00M | 168.00M | -291.65M | -195.37M | -179.12M | -13.04M | -33.33M | 55.48M | 91.12M |
| Financing Cash Flow | 478.00M | 399.00M | 388.00M | 501.21M | 118.55M | 600.27M | 679.31M | 336.85M | 136.27M | 138.68M |
| Net Change in Cash | 252.00M | -35.00M | 81.00M | -171.98M | -416.71M | 290.05M | 320.72M | 12.48M | -61.57M | 68.75M |
| Free Cash Flow | -472.00M | -421.00M | -519.00M | -496.59M | -411.79M | -176.13M | -370.21M | -294.64M | -256.64M | -171.16M |
This table shows 10 annual periods of Ultragenyx Pharmaceutical's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RARE's reporting calendar. What is a cash flow statement?